Article
AVEO Oncology and Astellas Pharma Inc. have announced that the FDA has accepted for filing the new drug application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma.
FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
PSMA-PET imaging product, Gozellix, launches on US market
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
Dipen Parekh, M.D. named Chief Executive Officer of the University of Miami Health System
Cleveland Clinic is First to Use Wireless, Catheter-Free Device to Monitor Bladder Dysfunction in Patients